GlobeNewswire Inc.··Not SpecifiedBiomea Fusion Slashes Q1 Loss 58% as Icovamenib Shows Promise in Diabetes Trial
Biomea Fusion cuts Q1 net loss 58% to $12.4M while advancing diabetes and obesity trials with positive early efficacy signals.
BMEAclinical trialsType 1 diabetes